PROM1 and acute lymphoblastic leukemia: Additionally, CD133 expression has been shown to be significantly correlated with a higher resistance to chemotherapeutic treatment and is associated with a tendency toward poorer outcomes, a higher incidence of relapse, and death, and vice versa, higher CR rates in CD133-negative ALL cases [22].